00:55 , Mar 16, 2018 |  BioCentury  |  Emerging Company Profile

Cirius safety

Cirius Therapeutics Inc. is developing a second-generation insulin sensitizer for non-alcoholic steatohepatitis that is designed to avoid cardiovascular symptoms and edema associated with first-generation agents. Insulin-sensitizing thiazolidinediones (TZDs) including Actos pioglitazone from Takeda Pharmaceutical Co. Ltd....
04:12 , Sep 16, 2017 |  BioCentury  |  Strategy

Passing the baton

When he takes the helm as CEO of Novartis AG in January, Vasant Narasimhan will inherit a business that is still struggling to plug the revenue hole from cancer drug Gleevec imatinib going off patent...
20:34 , Apr 21, 2017 |  BC Week In Review  |  Company News

Allergan, Novartis deal

The companies will test a combination including a farnesoid X receptor (FXR; NR1H4) agonist from Novartis and cenicriviroc from Allergan in a Phase IIb trial to treat non-alcoholic steatohepatitis (NASH). Two of Novartis’ FXR agonists,...
23:13 , Apr 18, 2017 |  BC Extra  |  Company News

Novartis, Allergan planning NASH combo trial

Novartis AG (NYSE:NVS; SIX:NOVN) and Allergan plc (NYSE:AGN) said they will test a combination including a farnesoid X receptor (FXR; NR1H4) agonist from Novartis and cenicriviroc (formerly TBR-652) from Allergan in a Phase IIb trial...
18:32 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Cenicriviroc: Additional Ph IIb data

Additional data from the double-blind, international Phase IIb CENTAUR trial in 289 NASH patients with liver fibrosis and diabetes or metabolic syndrome showed that 16% of patients receiving once-daily 150 mg oral cenicriviroc for 2...
07:00 , Oct 3, 2016 |  BioCentury  |  Strategy

Combo deals

Allergan plc's two NASH acquisitions give it the second biggest pipeline for the indication and enough mechanisms to develop in-house combinations that could target multiple drivers of the disease pathophysiology. Together, Allergan's Sept. 20 deals...
07:00 , Sep 26, 2016 |  BioCentury  |  Finance

A premium premium

The acquisition of Tobira Therapeutics Inc. (NASDAQ:TBRA) by Allergan plc (NYSE:AGN) suggests significant value exists for investors willing to sift through clinical trials that produce less than clear-cut results. In this case, long-time Tobira holders,...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

Cenicriviroc: Phase I started

Tobira began an open-label, U.S. Phase I trial to evaluate 5 mg oral evogliptin with or without 150 mg oral cenicriviroc in 12 healthy volunteers. Tobira has exclusive, worldwide rights to cenicriviroc from Takeda (see...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

Evogliptin: Phase I started

Tobira began an open-label, U.S. Phase I trial to evaluate 5 mg oral evogliptin with or without 150 mg oral cenicriviroc in 12 healthy volunteers. Tobira has exclusive, worldwide rights to cenicriviroc from Takeda...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Company News

Tobira, Allergan deal

Allergan will acquire Tobira for $28.35 per share in upfront cash plus a contingent value right (CVR) worth up to $49.84 per share tied to four development, regulatory and commercial milestones. If all the milestones...